Faeth Therapeutics, Inc
faeththerapeutics.comWhat Do They Do?
Develops an experimental oral combination therapy for endometrial and breast cancer, designed to inhibit multiple parts of a cancer-growth pathway.
10-K for FY2025, filed Mar 30, 2026Following the Acquisition, our lead program is PIKTOR, an investigational multi-node inhibitor, or MNI, of the PI3K/AKT/mTOR pathway in…View ↗
PIKTOR, our lead clinical candidate, is an oral MNI of the PI3K/AKT/mTOR pathway. PIKTOR is comprised of two independently dosed inhibitors…View ↗
PIKTOR’s design reflects a strategy of vertical pathway blockade, targeting PI3Kα upstream and mTORC1 and mTORC2 downstream, simultaneously…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 30, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 4, 2026
−$16MView ↗
- ▲ +224% (Loss)
- vs −$4.9M in Q2 FY2025
-
Jun 15, 2026
Faeth appointed Anand Parikh chief executive and Brian Stephenson chief financial officer
Sources
8-K, filed Jun 15, 2026
The Board of Directors (the “Board”) of the Company appointed Anand Parikh as President and Chief Executive Officer of the Company…View ↗
From immune antibodies to pathway drugs
The older report centered on a tumor-activated antibody platform and candidates targeting immune signals; the latest centers on PIKTOR, an oral combination targeting multiple parts of a cancer-growth pathway, while completing the remaining solnerstotug trial.
10-K for FY2022, filed Mar 29, 2023 10-K for FY2025, filed Mar 30, 2026
Who Do They Compete With?
Competes with Celcuity, Kazia Therapeutics, Relay Therapeutics, Eli Lilly, Novartis, OnKure Therapeutics, and Laekna Therapeutics
10-K for FY2025, filed Mar 30, 2026Gedatolisib, an IV pan-PI3K/mTOR inhibitor from Celcuity, whose New Drug Application for HR+/HER2-, PIK3CA wild-type metastatic breast…View ↗
Loading...
